期刊文献+

骨髓细胞免疫表型分析在低幼稚细胞骨髓增生异常综合征诊断中的价值 被引量:6

Diagnostic Significance of Immunophenotyping of Bone Marrow Cells in Myelodysplastic Syndrome without an Increase of Marrow Blasts
下载PDF
导出
摘要 本研究旨在探讨低幼稚细胞骨髓增生异常综合征(MDS)患者细胞免疫表型特征,确定其在诊断中的价值。应用流式细胞术(FCM)检测222例血细胞减少伴骨髓病态造血、骨髓幼稚细胞数<5%的患者的细胞免疫表型;测定成熟粒细胞群和单核细胞群的抗原跨阶段表达(粒系或单核系CD34或CD117表达或成熟粒细胞群HLADR的表达),抗原跨系列表达(粒系或单核系CD7或CD56表达),CD45/SSC异常(成熟粒细胞群或单核细胞群),分化抗原表达(粒细胞群CD13/CD16和单核细胞群HLA-DR表达缺失);确定阳性结果的敏感性与特异性。结果表明:在222例患者中经临床检测及鉴别诊断,有127例确定诊断为MDS,95例为非MDS(药物性粒细胞减少,自身免疫性血细胞减少及特发性血小板减少)。在成熟粒细胞群抗原跨阶段、跨系列表达,CD45/SSC及抗原分化异常的敏感性分别为31.5%、30.7%、49.6%和60.6%,其特异性分别为100%、100%、88.4%和52.6%。单核细胞群抗原跨阶段、跨系列表达、CD45/SSC及抗原分化异常的敏感性分别为2.3%、11%、37%和12.6%。特异性均为100%。在如上观察的粒细胞群和单核细胞群的8个项目中,≥2项异常的敏感性为77.9%,特异性为95.8%,阳性结果预测值为96.1%。结论:抗原的跨阶段表达、跨系列表达及CD45/SSC异常具有较高的特异性,但敏感性差;而分化抗原异常虽敏感性较高但特异性差。多项表达异常对于MDS的诊断具有较高的诊断特异性及敏感性。 This study was aimed to investigate the characteristics of immunophenotypes in the patients with myelodysplastic syndrome (MDS) without an increase of marrow blasts, and to confirm their diagnostic significance. Marrow cells from 222 patients with pancytonia, dysplastic changes in one or more hematopoietic lineages and blast cells less than 5% were analyzed by multiparametric flow cytometry(FCM). The abnormal immunophenotypes were evaluated in asynchronous antigen expression ( CD34 or CD117 in mature granulocytes or mature monocytes, HLA-DR in mature granulocytes), in cross-lineage antigen expression (CD7 or CD56 in granulocytes or monocytes ), in aberrant light-scatter (CIM5/SSC in mature granulocyte or monocyte) and in abnormal expression of differentiation antigen (CD13/CD16 pattern in granulocytes and HLA-DR under-expression in monocytes). The sensitivity and specificity of abnormal immunophenotypes were determined on diagnosis. Among 222 cases, 127 cases were diagnosed as MDS by traditional diagnostic method and 95 cases were non-MDS (drug-related neutropenia, autoimmune cytopenia and idiopathic thrombocytopenia). In mature granulocyte gate, the sensitivity of asynchronous, cross-lineage antigen expression, aberrant lightscatter of CD45/SSC and abnormal expression of differentiation antigen were 31.5% ,30.7% ,49.6% and 60. 6% respectively, and the specificity were 100%, 100% ,88.4% and 52.6% respectively. In monocyte gate, the sensitivity of asynchronous, cross-lineage antigen expression, aberrant light-scatter of CD45/SSC and abnormal expression of differentiation antigen were 2.3% ,11% ,37% and 12.6% respectively. The specificity was 100% in all of them. Among 8 above mentioned items, sensitivity of more than 2 abnormalities was 77.9%, and specificity was 95.8%. The positive predictive value was 96.1%. It is concluded that the abnormal expression of asynchronous, cross-lineage antigen expression, aberrant light-scatter of CD45/SSC have a high specificity and a low sensitivity for diagnosis of MDS. The abnormal expressions of differentiation antigens have a high sensitivity and a low specificity; however, the detection of multiple expression abnormalities possesses the high sensitivity and specificity for diagnosis of MDS.
出处 《中国实验血液学杂志》 CAS CSCD 2009年第6期1477-1481,共5页 Journal of Experimental Hematology
关键词 骨髓细胞 骨髓增生异常综合征 细胞免疫表型 bone marrow cell myelodysplastic syndrome immunoohenotype
  • 相关文献

参考文献16

  • 1Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer, 2007; 7:118-129.
  • 2Mohamedali A, Gaken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood,2007; 110:3365 - 3373.
  • 3Harada H, Harada Y. Point mutation in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Crit Rev Eukaryot Gene Expr,2005 ; 15 : 183 - 196.
  • 4Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia, 2006 ; 20 : 635 - 644.
  • 5Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, eytogenetic associations, and role in leukemic transformation. Blood, 2006; 108:3548 - 3555.
  • 6Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997 ; 89:2079 - 2088.
  • 7Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon : IARCPress. 2008 : 87 - 103.
  • 8徐娟,郭轶先,赵弘,惠吴函,万岁桂,孙雪静.骨髓增生异常综合征患者细胞免疫表型异常[J].中国实验血液学杂志,2009,17(4):894-897. 被引量:6
  • 9Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with the outcome after hematopoietic stem cell transplantation. Blood, 2003 ; 102:394 - 340.
  • 10Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002 ; 100:2292 - 2302.

二级参考文献26

  • 1李建勇,阮长耿,郑列林,王爱青,张学光,夏学鸣.219例成人急性白血病免疫表型特点[J].中国实验血液学杂志,1996,4(4):411-412. 被引量:3
  • 2王兴兵,姚军霞,郑金娥,刘隽,李小青,贺艳丽,喻竞明,杨晶,魏君,刘仲萍,黄士昂.115例急性髓细胞白血病多参数流式细胞术免疫表型分析[J].中国实验血液学杂志,2005,13(2):250-253. 被引量:20
  • 3孙秀丽,方美云,姜凤,荆源.免疫分型用于68例急性白血病的分型[J].中国实验血液学杂志,2006,14(1):39-41. 被引量:8
  • 4Heaney ML, Gold DW. Myelodysplasia. N Engl J Med, 1999; 340 : 1649 - 1660.
  • 5Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatdment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res, 2007 ;31:727 -736.
  • 6Nimer SD. Myelodysplastic Syndromes. Blood, 2008 ; 111 : 4841 -4851.
  • 7Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelo- dysplastic syndrome correlates with the IPSS and with the outcome after hematopoietic stem cell transplantation. Blood, 2003;102:394 - 403.
  • 8Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002 ; 100:2292 - 2302.
  • 9Jaffe ES, Harris NL, Stein H, et al. Tumours of Haematopoietic and Lymphoid Tissues. In: World Health Organization Classification of Tumours. Lyon, France: IARC Press. 2001:60-73.
  • 10Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997 ; 89 : 2097 -2088.

共引文献13

同被引文献42

  • 1陈书长,江滨,达万明,龚明,管梅.环孢素 A 对骨髓增生异常综合征的治疗作用研究[J].中华医学杂志,2006,86(38):2711-2715. 被引量:3
  • 2焦雪丽,陈子兴,岑建农,何军,刘丹丹,陈文明.MDS患者端粒相关蛋白TRF1基因的表达[J].中国血液流变学杂志,2007,17(1):1-3. 被引量:3
  • 3Arjan A, van de Loosdrecht, Canan A, et al. Standardization of flow cytometry in myelodysplastic syndromes:report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes [ J ]. Haematologica, 2009,94 ( 8 ) : 1124 - 1134.
  • 4Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation [ J ]. Blood, 2003, 102 : 394 - 403.
  • 5Stachurski D,Smith BR, Pozdnyakova O, et al. Flow cytometric analysis of myelomonocytic ceils by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases:emphasis on a global evaluation and recognition of diagnostic pitfalls [ J ]. Leuk Res, 2008,32 : 215 - 224.
  • 6Matarraz S, Lopez A, Barrena S, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34^+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors [ J ]. Leukemia. 2008; 22,1175 -1183.
  • 7Pedreira CE, Costa ES, Barrena S, et al. Generation of flow cytometry data flies with a potentially infinite number of dimensions [ J ]. Cytometry A ,2008,73:834 - 846.
  • 8Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of the haematopoietic and lymphoid tissues [ M]. 4 th ed. France : IARC, 2008:88-107.
  • 9Williamson PJ, Oscier DG, Bell A J, et al. Red cell aplasia in myelodysplastic syndrome [J]. J Clin Pathol, 1991,44 (5) :431-432.
  • 10Park S, Merlat A, Guesnu M,et al. Pure red cell aplasia associated with myelodysplastie syndromes[J].Leukemia, 2000,14(9) : 1709-1710.

引证文献6

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部